Aptose Biosciences (APTO) Year-over-year earnings per share growth for the last twelve months

Aptose Biosciences Inc. (APTO) is implementing robotic bioscreening and AI to accelerate drug discovery for hematological pathologies. The quarterly EPS growth rate allows investors to filter out market noise and identify the true trend, where 0.00 reflects the latest metric value. The company is valued for developing high-precision targeted therapies. Stable demand for innovation makes this sector a reliable defensive asset, independent of macroeconomic conditions.

aptose.com (APTO) - Year-over-year earnings per share growth for the last 12 months from 07/04/2022 to 04/13/2025

Analytical breakdowns for Aptose Biosciences Inc (APTO)

- market value and analyst target forecast:

Price Chart aptose.com|APTO - Average Forecast Price

- market capitalization details:

Market Value Aptose|APTO - Total Enterprise Value

- book capitalization data:

Book Value per Share Aptose Biosciences|APTO - Accounting Capitalization|Market Capitalization to Book Value Ratio aptose.com|APTO - Company Total Assets

- company liabilities and liquidity data:

- earnings and valuation multiples indicators:

APTO - Company Net Income|Future Profit Aptose Biosciences Inc.|APTO - Company Value to Net Income|Forward P/E Multiple Aptose Biosciences Inc|APTO - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Aptose Biosciences Inc|APTO - Operating income before deduction of amortization|Earnings per share for the last twelve months Aptose Biosciences|APTO - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months aptose.com|APTO - Expected net earnings per share growth this year|Earnings growth forecast for next year Aptose Biosciences Inc.

- company sales and revenue statistics:

APTO - Company Sales|Projected Sales Volume Aptose Biosciences Inc.|APTO - Price-to-Revenue Coefficient|Forward P/S Multiple Aptose|APTO - Trailing Twelve Months Revenue Growth

Fundamental company valuation:Aptose Biosciences Inc.

Manufactured product of Aptose Biosciences

The long-term reliability of Aptose Biosciences Inc. (APTO) is determined by management's ability to contain operating expenses relative to net income. By analyzing the growth rates of quarterly net income per share, investors assess the dynamics of per-unit income, which, under conditions of strict liquidity austerity and organic growth, confirms the effectiveness of seeking strategic alliances for the joint funding of clinical trials.

Analysis of competing companies